CN111448217A - 双特异性抗原结合构建体 - Google Patents

双特异性抗原结合构建体 Download PDF

Info

Publication number
CN111448217A
CN111448217A CN201880078802.0A CN201880078802A CN111448217A CN 111448217 A CN111448217 A CN 111448217A CN 201880078802 A CN201880078802 A CN 201880078802A CN 111448217 A CN111448217 A CN 111448217A
Authority
CN
China
Prior art keywords
val
ser
pro
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880078802.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·布朗什托
S·范德旺宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64959348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111448217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of CN111448217A publication Critical patent/CN111448217A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880078802.0A 2017-12-22 2018-12-21 双特异性抗原结合构建体 Pending CN111448217A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609523P 2017-12-22 2017-12-22
US62/609,523 2017-12-22
PCT/EP2018/086755 WO2019122409A1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Publications (1)

Publication Number Publication Date
CN111448217A true CN111448217A (zh) 2020-07-24

Family

ID=64959348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880078802.0A Pending CN111448217A (zh) 2017-12-22 2018-12-21 双特异性抗原结合构建体

Country Status (9)

Country Link
US (2) US12071486B2 (https=)
EP (2) EP4495142A3 (https=)
JP (2) JP7657591B2 (https=)
CN (1) CN111448217A (https=)
AU (1) AU2018387829B2 (https=)
CA (1) CA3079793A1 (https=)
DK (1) DK3728328T5 (https=)
IL (1) IL274676A (https=)
WO (1) WO2019122409A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525275A (ja) * 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
CN114981308A (zh) * 2020-01-19 2022-08-30 南京金斯瑞生物科技有限公司 多特异性抗密蛋白-18.2构建体及其用途
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
AU2024210302A1 (en) * 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies
US20140079689A1 (en) * 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
JP2017536829A (ja) * 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
BR9813276A (pt) 1997-10-27 2000-08-22 Unilever Nv Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
AU2008328726B2 (en) 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
JP5816170B2 (ja) * 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
PT2825559T (pt) 2012-03-13 2019-06-07 Novimmune Sa Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US11261262B2 (en) * 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105814082A (zh) 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
IL262241B2 (en) 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
SI3468586T1 (sl) * 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165621A1 (en) * 2010-01-04 2011-07-07 arGEN-X BV Humanized antibodies
US20140079689A1 (en) * 2011-02-04 2014-03-20 Genentech, Inc. Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
JP2017536829A (ja) * 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER BANNAS: "Nanobodies and nanobody/based human heavy chainantibodies as antitumor therapeutics", 《FRONTIERS IN IMMUNOLOGY》 *
ULRICH BRINKMANN 等: ""The making of bispecific antibodies", 《MABS》 *

Also Published As

Publication number Publication date
DK3728328T3 (da) 2025-01-02
JP2023139025A (ja) 2023-10-03
EP4495142A2 (en) 2025-01-22
AU2018387829A1 (en) 2020-05-07
JP2021506310A (ja) 2021-02-22
EP3728328A1 (en) 2020-10-28
EP4495142A3 (en) 2025-05-07
CA3079793A1 (en) 2019-06-27
DK3728328T5 (da) 2025-02-17
EP3728328B1 (en) 2024-10-23
IL274676A (en) 2020-06-30
US20190218310A1 (en) 2019-07-18
US20240368311A1 (en) 2024-11-07
AU2018387829B2 (en) 2024-12-19
WO2019122409A1 (en) 2019-06-27
US12071486B2 (en) 2024-08-27
JP7657591B2 (ja) 2025-04-07

Similar Documents

Publication Publication Date Title
JP6742245B2 (ja) 多重特異性抗体
CN103068846B (zh) 包含二硫键稳定性Fv片段的双特异性抗体
CN102803295B (zh) 双特异性、四价抗原结合蛋白
RU2570633C2 (ru) Три- или тетраспецифические антитела
US20240368311A1 (en) Bispecific antigen binding construct
TW202144431A (zh) 工程化抗her2雙特異性蛋白
CN117120478A (zh) 一种抗原结合分子
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
AU2024233425A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
WO2026056998A1 (zh) Gipr结合分子及医药用途
AU2024233602A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024107731A2 (en) Anti-pd-l1 antibodies
AU2023367039A1 (en) Anti-cd3 antibodies
HK40076302A (en) New polypeptide complex

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination